Concepedia

Jaymes Holland

JH

18

Publications

1.3K

Citations

16

H-Index

1993

Active since

Affiliations

Exelixis (United States)(Current)

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

The Barbara Ann Karmanos Cancer Institute

Comprehensive Cancer Centers of Nevada

Jaymes Holland is an author at Exelixis (United States) specializing in medicine, oncology, and pharmacology.

Top concepts

Publications per year

1993–2019

18

Publications

18

A randomised comparison of deferasirox<i>versus</i>deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Elliott Vichinsky, Onyinye Onyekwere, John B. Porter et al. · British Journal of Haematology · 2006 · 270 citations · Full text

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

Toni K. Choueiri, Sumanta K. Pal, David F. McDermott et al. · Annals of Oncology · 2014 · 160 citations · Full text

, , +7

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

Patrick Y. Wen, Jan Drappatz, John de Groot et al. · Neuro-Oncology · 2017 · 112 citations · Full text

A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

Maria E. Cabanillas, Marcia S. Brose, Jaymes Holland et al. · Thyroid · 2014 · 86 citations · Full text

Inflammation and oxidant-stress in  -thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

P. B. Walter, Eric A. Macklin, John B. Porter et al. · Haematologica · 2008 · 82 citations · Full text

Rows per page

1–5 of 18